Source:http://linkedlifedata.com/resource/pubmed/id/21126942
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2010-12-17
|
pubmed:abstractText |
Overproduction of inflammation-related cytokines plays an important role in systemic lupus erythematosus (SLE). A crucial cytokine is IL-18, a member of the IL-1 family involved in the regulation of both innate and acquired immune responses. The aim of this study was to evaluate free IL-18 levels in the serum and urine of SLE patients, in order to establish their relationship with other biomarkers of disease activity. Serum and urine levels of IL-18 and IL-18BP were measured by ELISA in 50 SLE patients and in 32 healthy subjects; free IL-18 was calculated using the law of mass action. Serum levels of total IL-18, IL-18BP and free IL-18 were higher in SLE patients than in healthy controls. Total and free serum IL-18 levels were higher in patients with active disease (with nephritis or active non-renal disease), and correlated with the ECLAM score. Urinary levels of total and free IL-18 were higher in patients than in controls, but did not correlate with disease activity. The data collected in this study show that increased levels of both IL-18 and its natural inhibitor IL-18BP, characterise SLE. Despite the overproduction of IL-18BP, free IL-18 is still significantly higher in SLE patients than in controls, and its serum levels are a marker of disease activity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-18,
http://linkedlifedata.com/resource/pubmed/chemical/interleukin-18 binding protein
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1148-5493
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
264-71
|
pubmed:meshHeading |
pubmed-meshheading:21126942-Adolescent,
pubmed-meshheading:21126942-Adult,
pubmed-meshheading:21126942-Aged,
pubmed-meshheading:21126942-Biological Markers,
pubmed-meshheading:21126942-Cohort Studies,
pubmed-meshheading:21126942-Female,
pubmed-meshheading:21126942-Follow-Up Studies,
pubmed-meshheading:21126942-Humans,
pubmed-meshheading:21126942-Intercellular Signaling Peptides and Proteins,
pubmed-meshheading:21126942-Interleukin-18,
pubmed-meshheading:21126942-Lupus Erythematosus, Systemic,
pubmed-meshheading:21126942-Male,
pubmed-meshheading:21126942-Middle Aged,
pubmed-meshheading:21126942-Severity of Illness Index,
pubmed-meshheading:21126942-Young Adult
|
pubmed:year |
2010
|
pubmed:articleTitle |
Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus.
|
pubmed:affiliation |
Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Via Roma 67, Pisa, Italy. p.migliorini@med.unipi.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|